🍽️ GI Cancer — 2026-W42

What this page is. Every paper the week's monitor reviewed — including the ones that did not go into the digest. Material marked “Not selected” was reviewed and deliberately left out. It has not been fact-checked to digest standard and is not endorsed. For the curated read, see the digest itself.

Review in Clin Cancer Res on RAS-targeted therapies in metastatic pancreatic cancer, centered on agents in phase 3 trials after daraxonrasib's approval. Informs oncologists about the evolving treatment landscape and ongoing trials.

Systematic review and meta-analysis of observational studies comparing early-onset and average-onset pancreatic cancer, published in JNCI. Finds similar survival despite more advanced presentation and more chemotherapy in younger patients, though certainty of evidence is very low.

Randomized phase 2 trial in RAS wild-type refractory metastatic colorectal cancer comparing regorafenib followed by anti-EGFR therapy versus the reverse sequence, published in The Oncologist. Closed early for poor accrual, so it is underpowered and does not settle optimal sequencing.

Retrospective cohort in MEN1-associated metastatic duodenopancreatic NET versus sporadic pancreatic NET treated with 177Lu-Dotatate, published in Endocr Relat Cancer. Suggests outcomes are similar to sporadic disease, supporting PRRT use in MEN1 patients.

Translational chromatin accessibility study in gastric cancer, published in Cancer Cell. Identifies an epigenomic subtype resistant to immunotherapy and proposes acid blockade as a way to sensitize, but this remains hypothesis-generating.

Real-world clinicogenomic database analysis in adults with advanced solid tumors, published in JCO Precision Oncology. Uses matched emulation to assess whether NTRK fusions affect survival independent of TRK inhibitor therapy, informing prognostic interpretation rather than treatment selection.

Preclinical study of CDH17-directed antibody-drug conjugates in colorectal cancer models, published in Clinical Cancer Research. Suggests exatecan payloads overcome P-gp resistance but face target-mediated clearance, informing early ADC development.

Preclinical mouse and multiomics study in colorectal cancer, published in Nature Cancer. Identifies a GSK3β-driven neutrophil reprogramming axis and suggests GSK3β inhibition could enhance checkpoint blockade, but remains hypothesis-generating.